New therapies for asthma: where next?
Robinson
Douglas S
DS
Department of Allergy, National Heart and Lung Institute and Basic Medical Sciences Division, Faculty of Medicine, Imperial College London, London, UK. d.s.robinson@imperial.ac.uk
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002648:Child; D016207:Cytokines / Q000037:antagonists & inhibitors; D003888:Desensitization, Immunologic / Q000379:methods; D005544:Forecasting; D006801:Humans; D007223:Infant; D015847:Interleukin-4 / Q000037:antagonists & inhibitors; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D015272:Pulmonary Medicine / Q000639:trends*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000888:Antibodies, Anti-Idiotypic; D016207:Cytokines; D015848:Interleukin-5; D014409:Tumor Necrosis Factor-alpha; C026408:anti-IgE antibodies; D015847:Interleukin-4